XOMA Royalty Corporation (XOMA)
NASDAQ: XOMA · Real-Time Price · USD
33.35
-1.45 (-4.15%)
At close: Oct 29, 2025, 4:00 PM EDT
33.35
+0.01 (0.01%)
After-hours: Oct 29, 2025, 5:20 PM EDT
XOMA Royalty Revenue
XOMA Royalty had revenue of $13.13M in the quarter ending June 30, 2025, with 18.43% growth. This brings the company's revenue in the last twelve months to $44.95M, up 194.98% year-over-year. In the year 2024, XOMA Royalty had annual revenue of $28.49M with 498.72% growth.
Revenue (ttm)
$44.95M
Revenue Growth
+194.98%
P/S Ratio
8.82
Revenue / Employee
$3,457,846
Employees
13
Market Cap
403.06M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.49M | 23.73M | 498.72% |
| Dec 31, 2023 | 4.76M | -1.27M | -21.06% |
| Dec 31, 2022 | 6.03M | -32.13M | -84.21% |
| Dec 31, 2021 | 38.16M | 8.78M | 29.86% |
| Dec 31, 2020 | 29.39M | 11.02M | 59.96% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
XOMA News
- 12 days ago - XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement - GlobeNewsWire
- 26 days ago - XOMA Royalty PFD Update: Going Back To My Original Sell Ratings - Seeking Alpha
- 27 days ago - XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V. - GlobeNewsWire
- 5 weeks ago - ESSA Pharma Inc. Amends Agreement with XenoTherapeutics - PRNewsWire
- 5 weeks ago - XOMA Royalty Declares Quarterly Preferred Stock Dividends - GlobeNewsWire
- 6 weeks ago - XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc. - GlobeNewsWire
- 2 months ago - XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share - GlobeNewsWire